- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01610427
Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects
Optimizing the Quality of Samples Used for the Evaluation of Cell-mediated Immune (CMI) Responses in Antiretroviral Therapy (ART)-naïve Human Deficiency Virus Type 1 (HIV-1)-Infected Subjects
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Gent, Belgia, 9000
- GSK Investigational Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
All subjects must satisfy all the following criteria at study entry:
- Subjects who the Investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject prior to any study procedure.
- A male or female between and including 18 and 55 years of age at the time of enrollment.
- Confirmed HIV-1 infection.
- ART-naïve and not eligible for ART treatment as per established guidelines. Subjects must never have received ART after HIV diagnosis, including lamivudine used for chronic hepatitis B infection. The exception to this is short-term ART for prevention of mother-to-child transmission (PMTCT) which must have been completed at least 360 days prior to enrollment.
- Viral load level between and including 2,000 and 100,000 copies/mL at screening.
- CD4+ T cell count >500 cells/mm3 at screening.
If the subject is female, she must be of non-childbearing potential, i.e., have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal. Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test at screening, and
- has agreed to continue adequate contraception during the entire study period.
Exclusion Criteria:
The following criteria should be checked at the time of study entry. If any exclusion criterion applies, the subject must not be included in the study:
- Infection with HIV-2. This includes subjects with dual infection with HIV-1/HIV-2.
- Planned use of any hematotoxic product during the study period.
- Planned use of any investigational or non-registered product during the study period.
- Acute or chronic, clinically relevant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination, serology and/or medical history at screening.
- Grade 3 or grade 4 laboratory abnormalities, as defined by Division of AIDS (DAIDS) grading table, at screening.
- Any condition which, in the opinion of the Investigator, could compromise the subject's adherence to the study protocol.
- Planned administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the Sample Collection Visit (Visit 2). Vaccine can be administered as after sampling in Visit 2.
- Pregnant or lactating female.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Podstawowa nauka
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: HIV-1 Group
Antiretroviral Therapy-naïve HIV1-infected subjects, aged 18 to 55 years, from whom samples for cell-mediated immunity (CMI) were collected.
No investigational vaccine was administered.
|
Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Lymphocytes Viability Prediction (LOGIT Transformed) in CMI Samples Post-overnight Incubation Time Before Intracellular Cytokine Staining (ICS): "Intercept" Parameter Estimate of the Prediction Model - Condition "None" Resting Time Not Included
Ramy czasowe: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10^P/(1 + 10^P)*100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting the intercept i.e. expected mean value of Prediction when "TP" and "RT" = 0.
The optimum of this Design of Experiment is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Time to Process and Resting Time Parameter Estimates of the Prediction Model - Condition "None" Resting Time Not Included
Ramy czasowe: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting "TP" and "RT" estimates expressed as log(hours).
The optimum of this Design of Experiment (DOE) is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: TP*RT, TP*TP and RT*RT Parameter Estimates of the Prediction Model - Condition "None" Resting Time Not Included
Ramy czasowe: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting TP*RT, TP*TP and RT*RT estimates expressed as log(hours^2).
The optimum of this DOE is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Optimum Mean Cell Viability Estimate by the Prediction Model - Condition "None" Resting Time Not Included
Ramy czasowe: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
The optimum predicted mean cell viability of this Design of Experiment is presented in this outcome and expressed as percentage.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: "Intercept" Parameter Estimate of the Prediction Model - Condition "None" Resting Time Included
Ramy czasowe: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting the intercept i.e. expected mean value of Prediction when "TP" and "RT" = 0.
The optimum of this Design of Experiment is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Time to Process and Resting Time Parameter Estimates of the Prediction Model - Condition "None" Resting Time Included
Ramy czasowe: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting "TP" and "RT" estimates expressed as log(hours).
The optimum of this Design of Experiment (DOE) is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: TP*RT and RT*RT Parameter Estimates of the Prediction Model - Condition "None" Resting Time Included
Ramy czasowe: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting TP*RT and RT*RT estimates expressed as log(hours^2).
The optimum of this DOE is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Optimum Mean Cell Viability Estimates by the Prediction Model -Condition "None" Resting Time Included.
Ramy czasowe: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
The optimum predicted mean cell viability of this Design of Experiment is presented in this outcome and expressed as percentage.
|
At Day 15 (sample collection visit)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Viable Lymphocytes in the CMI Samples, Post-overnight Incubation (Classic) Before ICS and Post-6 Hour Incubation Before ICS
Ramy czasowe: A Day 15 (sample collection visit)
|
The percentage of viable lymphocytes was determined by Forward Scatter/Side Scatter (FSC/SSC) and LIVE/DEAD gating during flow cytometry analysis for each incubation of time-to-time process (TP) = 2h, 7h and 24 h and resting time (RT) = 18h for the comparison of resting time = 18h and classic incubation time versus resting time = 18h and post-6h incubation time.
|
A Day 15 (sample collection visit)
|
Magnitude of HIV-1 RT Specific Cluster of Differentiation 40 Ligand (CD40L+) CD4+ T Cell Responses in the CMI Samples Post-overnight ICS/Post 6 Hour ICS, Expressing at Least One Cytokine
Ramy czasowe: At Day 15 (sample collection visit)
|
Data were collected but could not be reported as data were below level of detection.
|
At Day 15 (sample collection visit)
|
Magnitude of HIV-RT Specific (Background Reduced) CD8+ T Cell Responses in the CMI Samples Post-overnight ICS/Post 6 Hour ICS, Expressing at Least One Cytokine
Ramy czasowe: At Day 15 (sample collection visit)
|
HIV-RT specific responses of CD8+ T cells expressing at least one cytokine, among: Interleukin-2 (IL-2), Interferon-gamma (IFN-g) and Tumor necrosis factor alpha (TNF-a),after stimulation with HIV-1 peptide pools for time-to-process (TP) (2, 7, 24 hours) and resting time (RT) (0,2,6,18 hours) post-overnight ICS and for time-to-process (7 hours) and resting time (18 hours) post 6 hours ICS.
|
At Day 15 (sample collection visit)
|
Number of Subjects With Serious Adverse Events (SAEs)
Ramy czasowe: During the whole study period (From Day 0 to Day 15)
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitali-zation or prolongation of hospitalization or result in disability/incapacity.
|
During the whole study period (From Day 0 to Day 15)
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- 116329
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na AIDS
-
University of MinnesotaWycofaneZakażenia wirusem HIV | HIV/AIDS | HIV | AIDS | Problem z AIDS/HIV | AIDS i infekcjeStany Zjednoczone
-
Cell Energy Life Sciences Group Co. LTDBeijing YouAn Hospital; Beijing 302 Hospital; Shenzhen Third People's Hospital; Fifth...Rekrutacyjny
-
ViiV HealthcarePfizerZakończony
-
Beijing 302 HospitalShanghai Public Health Clinical Center; The 6th people's Hospital of Xinjiang... i inni współpracownicyRekrutacyjnyPacjenci z AIDSChiny
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLCZakończonyChłoniak obwodowy/układowy związany z AIDS | Rozlany chłoniak wielkokomórkowy związany z AIDS | Chłoniak rozlany z komórek mieszanych związany z AIDS | Rozlany chłoniak drobnokomórkowy związany z AIDS | Immunoblastyczny chłoniak wielkokomórkowy związany z AIDS | Chłoniak limfoblastyczny związany... i inne warunkiZimbabwe, Kenia
-
Juan A. ArnaizNieznany
-
Duke UniversityThe University of Hong Kong; Oxford University Clinical Research Unit, Vietnam; National Hospital for Tropical Diseases, Hanoi, Vietnam i inni współpracownicyAktywny, nie rekrutującyAIDS/HIV - związaneChoroba związana z AIDSWietnam
-
HeNan Sincere Biotech Co., LtdBeijing YouAn Hospital; Beijing Ditan Hospital; Peking Union Medical College Hospital i inni współpracownicyZakończony
-
GlaxoSmithKlineZakończony
Badania kliniczne na Blood sample collection
-
Cliniques universitaires Saint-Luc- Université...Université de LiègeRekrutacyjnyMukowiscydoza | BiomarkeryBelgia
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RekrutacyjnyRakotwórcza otrzewnej | Nowotwór układu pokarmowego | Rak wątroby i dróg żółciowych wewnątrzwątrobowych | Rak wyrostka robaczkowego według etapu AJCC V8 | Rak jelita grubego wg AJCC V8 Stage | Rak przełyku według etapu AJCC V8 | Rak żołądka wg AJCC V8 StageStany Zjednoczone
-
Memorial Sloan Kettering Cancer CenterZakończonyRak prostatyStany Zjednoczone
-
Applied Science & Performance InstituteZakończonyNiedobór żelaza (bez niedokrwistości)Stany Zjednoczone
-
Ischemia Care LLCZakończonyUdar niedokrwienny | Migotanie przedsionków | Udar zakrzepowy | Przejściowe ataki niedokrwienne | Udar sercowo-zatorowy | Udar tętnicy podstawnej | Przejściowe zdarzenia naczyniowo-mózgoweStany Zjednoczone
-
George Fox UniversityNieznanySłabe mięśnie | Czy terapia ograniczająca przepływ krwi zwiększa wzrost siły w mankiecie rotatorówStany Zjednoczone
-
Christopher BellZakończonyĆwiczenie wytrzymałościoweStany Zjednoczone
-
Immodulon Therapeutics LtdZakończonyCzerniakZjednoczone Królestwo
-
Reham HassanZakończonyWpływ elementówEgipt
-
University Hospital, Clermont-FerrandCentre Jean PerrinNieznanyKwantyfikacja spoczynku/stresu dyssynchronii lewej komory za pomocą bramkowanej puli krwi 3D D-SPECTDyssynchronia lewej komoryFrancja